Johnson JR - Search Results

1

FDA drug approval summary: erlotinib (Tarceva) tablets.

Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. Cohen MH, et al. Among authors: johnson jr. Oncologist. 2005 Aug;10(7):461-6. doi: 10.1634/theoncologist.10-7-461. Oncologist. 2005. PMID: 16079312 Free article. Clinical Trial.

2

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R. Ryan Q, et al. Oncologist. 2008 Oct;13(10):1114-9. doi: 10.1634/theoncologist.2008-0816. Epub 2008 Oct 10. Oncologist. 2008. PMID: 18849320 Free article. Clinical Trial.

3

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Cohen MH, et al. Among authors: johnson jr. Clin Cancer Res. 2002 Mar;8(3):665-9. Clin Cancer Res. 2002. PMID: 11895893

4

FDA drug approval summaries: pemetrexed (Alimta).

Hazarika M, White RM, Johnson JR, Pazdur R. Hazarika M, et al. Among authors: johnson jr. Oncologist. 2004;9(5):482-8. doi: 10.1634/theoncologist.9-5-482. Oncologist. 2004. PMID: 15477632 Free article. Review.

5

U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.

Cohen MH, Johnson JR, Pazdur R. Cohen MH, et al. Among authors: johnson jr. Clin Cancer Res. 2005 Jan 1;11(1):12-9. Clin Cancer Res. 2005. PMID: 15671523 Clinical Trial.

6

FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.

Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. Cohen MH, et al. Among authors: johnson jr. Oncologist. 2005 Jun-Jul;10(6):363-8. doi: 10.1634/theoncologist.10-6-363. Oncologist. 2005. PMID: 15967829 Free article. Clinical Trial.

7

Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.

Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Mann BS, et al. Among authors: johnson jr. Clin Cancer Res. 2005 Aug 15;11(16):5671-7. doi: 10.1158/1078-0432.CCR-05-0354. Clin Cancer Res. 2005. PMID: 16115902

8

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R. Johnson JR, et al. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. doi: 10.1158/1078-0432.CCR-05-0790. Clin Cancer Res. 2005. PMID: 16166415 Clinical Trial.

9

Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.

Cohen MH, Johnson JR, Pazdur R. Cohen MH, et al. Among authors: johnson jr. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6767-71. doi: 10.1158/1078-0432.CCR-05-0722. Clin Cancer Res. 2005. PMID: 16203762 Clinical Trial.

10

Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.

Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD Jr, Abraham S, Booth BP, Goheer MA, Morse D, Chen XH, Chidambaram N, Kenna L, Gobburu JV, Justice R, Pazdur R. Cohen MH, et al. Among authors: johnson jr. Clin Cancer Res. 2006 Sep 15;12(18):5329-35. doi: 10.1158/1078-0432.CCR-06-0606. Clin Cancer Res. 2006. PMID: 17000665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,181 results

Search Page

Filters